Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Great Novel Therapeutics Biotech & Medicals has the GF Score of 43, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Novel Therapeutics Biotech & Medicals GF Score vs Biotechnology Industry
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a GF Score of 43 as of Jul. 24, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. This is 187% above median its historical median of 15.00. Over the past decade, Great Novel Therapeutics Biotech & Medicals' GF Score has ranged from 5.00 to 55.00.
Is Great Novel Therapeutics Biotech & Medicals' GF Score too high?
Great Novel Therapeutics Biotech & Medicals' current GF Score of 43 is 187% above median its 10-year median of 15.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 55.00. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' GF Score compare to VRTX and REGN?
Great Novel Therapeutics Biotech & Medicals' GF Score of 43 can be compared against companies in the Biotechnology industry. Historically, Great Novel Therapeutics Biotech & Medicals' own GF Score has ranged from 5.00 to 55.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current GF Score is 43, which is 187% above median its own 10-year median of 15.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.80, compared to a current price of NT$75.30 — trading 191.9% above its estimated fair value. The current GF Score is 43, which is 187% above median its 10-year median of 15.00. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current GF Score is 43 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued.
The current stock price of NT$75.30 is trading 191.9% above its estimated GF Value™ of NT$25.80.
GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.
Key valuation signals for ROCO:7427:
GF Score: 43 (187% above median its 10-year median of 15.00)
GF Value™: NT$25.80 vs. price of NT$75.30 (191.9% above fair value)
No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Novel Therapeutics Biotech & Medicals Business Description
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
43GF Score
Get the complete analysis for ROCO:7427
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7427 has been successfully added to your 
